In this study, we explored the therapeutic efficacy of CCR2/5 inhibition and FGF21 agonism using two novel pharmacological compounds in mouse models of liver injury and NASH. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.